TY - T1的支气管肺泡灌洗液淋巴球增多在慢性过敏性肺炎:系统回顾和荟萃分析JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00206 -2020欧元SP - 2000206 AU -尼古拉Adderley AU -克里斯托弗·J·汉弗莱斯AU -海莉巴恩斯AU -布雷特雷盟-普莱姆基Zahra A . AU -克利的A·约翰森Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/04/01/13993003.00206 - 2020. -抽象N2 -背景的角色支气管肺泡灌洗液(BAL)淋巴细胞百分比诊断慢性过敏性肺炎(CHP)尚不清楚。我们进行了一项系统回顾和荟萃分析BAL淋巴细胞百分比的共和人民党(CHP)的诊断。方法:我们搜查了Medline、Embase和Cochrane图书馆从开始到2019年8月。个体患者数据得到测试的性能特征BAL淋巴细胞百分比在不同的阈值。随机模型用于汇集估计,与对比CHP non-CHP间质性肺病(ILD)。53的研究结果包括在系统回顾和荟萃分析42。BAL淋巴细胞百分比的汇集估计为42.8% (95% CI 37.7 - -47.8, I2 = 95.3%)在CHP, 10.0% (95% CI 6.9 - -13.1, I2 = 91.2%)在特发性肺纤维化(IPF), 23.1% (95% CI 3.0 - -43.2, I2 = 85.2%)在non-IPF特发性间质性肺炎(IIP), 23.4% (95% CI 11.0 - -35.9, I2 = 45.7%)在结缔组织疾病ILD (CTD-ILD)和31.2% (95% CI 17.6 - -44.8, I2 = 95.2%)在结节病。结果不同CHP和IPF(术中;0.0001)之间,non-IPF IIP (p = 0.0309),和CTD-ILD (p = 0.0824),但不是在结节病(p = 0.0966)。从8个研究使用个别病人数据,淋巴细胞百分比阈值在20%提供CHP的敏感性为68.1%,特异性为64.8%。高阈值提供低敏感性较高的特异性。老年和曾经吸烟降低淋巴细胞在CHP %。结论BAL淋巴细胞百分比更高CHP IPF和其他IIP相比,高阈值提供改进的特异性灵敏度的成本。 However, parent studies are at risk of incorporation bias, and prospective studies should evaluate the additive discriminate value of BAL lymphocyte% to accurately diagnose CHP.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Adderley has nothing to disclose.Conflict of interest: Dr. Humphreys has nothing to disclose.Conflict of interest: Dr. Barnes has nothing to disclose.Conflict of interest: Dr. Ley has nothing to disclose.Conflict of interest: Dr. Premji has nothing to disclose.Conflict of interest: Dr. Johannson reports personal fees and other from Boehringer-Ingelheim, personal fees and other from Hoffman La Roche Ltd, personal fees and other from Theravance, personal fees and other from Blade Therapeutics, grants from Chest Foundation, grants from University of Calgary School of Medicine, grants from Pulmonary Fibrosis Society of Calgary, grants from UCB Biopharma SPRL, outside the submitted work. ER -